Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization.

Autor:	Tedjawirja VN; Department of Surgery, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre (UMC), University of Amsterdam, Amsterdam, Netherlands., Hooijer GKJ; Department of Pathology, Amsterdam University Medical Centre (UMC), University of Amsterdam, Amsterdam, Netherlands., Savci-Heijink CD; Department of Pathology, Amsterdam University Medical Centre (UMC), University of Amsterdam, Amsterdam, Netherlands., Kovac K; Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre (UMC), University of Amsterdam, Amsterdam, Netherlands., Balm R; Department of Surgery, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre (UMC), University of Amsterdam, Amsterdam, Netherlands., de Waard V; Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre (UMC), University of Amsterdam, Amsterdam, Netherlands.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Feb 16; Vol. 14, pp. 1095031. Date of Electronic Publication: 2023 Feb 16 (Print Publication: 2023).
DOI:	10.3389/fendo.2023.1095031
Abstrakt:	Introduction: Recently, follicle stimulating hormone (FSH) through interaction with its receptor (FSHR) has been proposed to play a role in postmenopausal osteoporosis and cardiovascular disease, rather than the loss of estrogen. To explore this hypothesis, unravelling which cells express extragonadal FSHR on protein level is key. Methods: We used two commercial anti-FSHR antibodies and validated them by performing immunohistochemistry on positive (ovary, testis) and negative controls (skin). Results: The monoclonal anti-FSHR antibody could not identify the FSHR in ovary or testis. The polyclonal anti-FSHR antibody stained the granulosa cells (ovary) and Sertoli cells (testis), yet there was equally intense staining of other cells/extracellular matrix. Furthermore, the polyclonal anti-FSHR antibody also stained skin tissue extensively, suggesting that the antibody stains more than just FSHR. Discussion: The findings in this study may add accuracy to literature on extragonadal FSHR localization and warrants attention to the use of inadequate anti-FSHR antibodies to value the potential role of FSH/FSHR in postmenopausal disease. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Tedjawirja, Hooijer, Savci-Heijink, Kovac, Balm and de Waard.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu